Novavax Inc
NASDAQ:NVAX

Watchlist Manager
Novavax Inc Logo
Novavax Inc
NASDAQ:NVAX
Watchlist
Price: 8.845 USD -5.1%
Market Cap: 1.4B USD
Have any thoughts about
Novavax Inc?
Write Note

Novavax Inc
Other Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Novavax Inc
Other Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Novavax Inc
NASDAQ:NVAX
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Receivables
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novavax Inc
Glance View

Market Cap
1.4B USD
Industry
Biotechnology

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 1,541 full-time employees. The firm promotes improved health globally through the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. Its recombinant technology platform harnesses the power and speed of genetic engineering to produce immunogenic nanoparticles designed to address urgent global health needs. The vaccine candidates in its near-term pipeline, including both coronavirus vaccine candidate (NVX-CoV2373) and seasonal quadrivalent influenza vaccine candidate (NanoFlu), which are genetically engineered, three-dimensional nanostructures of recombinant proteins critical to disease pathogenesis. NVX-CoV2373 is marketed under the brand name of Covovax or as Nuvaxovid COVID-19 Vaccine (SARS-CoV-2 rS [Recombinant, adjuvanted]).

NVAX Intrinsic Value
7.401 USD
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Novavax Inc's Other Receivables?
Other Receivables
0 USD

Based on the financial report for Sep 30, 2024, Novavax Inc's Other Receivables amounts to 0 USD.

Back to Top